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Abstract 
Background: Malignant melanoma of oral cavity is a rare condition, accounting for 0.5 % of all oral malignancies and 
about 1–2 % of all melanomas. Oral melanomas have extremely poor prognosis with 5 years survival rate of 12.3 %. 
The poor prognosis compared to cutaneous melanoma may be attributed to delay in reporting by patient and diag-
nosis, and apt to become ulcerated due to repeated trauma. The ‘chameleonic’ presentation of a mainly asymptomatic 
condition, the rarity of these lesions, the poor prognosis and the necessity of a highly specialized treatment are factors 
that should be seriously considered by the involved health provider.
Case presentation: We present a case of 32 years old male of Han ethnicity with mucosal melanoma of upper lip, 
comparing his clinical presentation and histological findings at his first visit and following the recurrence. The patient 
complained of black discoloration on the left side of upper lip since 4 years which gradually increased in size and later 
involved the skin of the lip. Excision with 5 mm safety margin was performed but the patient presented with the simi-
lar lesion after three and half years of the treatment. So, again wide excision with 2 cm safety margin was performed 
followed by reconstruction of the lip.
Conclusion: This case provides an example of aggressive behavior of mucosal melanoma and emphasizes on the 
fact that any pigmented lesion detected in the oral cavity may exhibit potential growth and should be submitted to 
biopsy to exclude malignancy. It also exemplifies of how the time of diagnosis and the evolution of a disease could be 
seriously influenced by patient’s behavior.
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Background
Malignant melanoma is a malignant neoplasm of mel-
anocytes or of melanocytic precursors [1]. Primary 
mucosal melanomas of the head and neck are rarer than 
cutaneous melanoma. Among those of the head and neck 
region, oral mucosal melanoma is extremely infrequent 
accounting for only 0.5  % of oral neoplasms and 1–2  % 
of all melanomas. Primary oral melanoma is a rare neo-
plasm arising from uncontrolled growth of melanocytes 
found in the basal layers of oral mucosal epithelium. 
Melanocytes are derived from neural crest cells and 
migrate to several sites, including skin and mucous mem-
brane [2]. Oral mucosal melanomas are highly malignant 
tumors with the tendency to metastasize or locally invade 
tissues more readily than other malignant tumors of the 
oral cavity [3]. Hard palate and maxillary gingiva are the 
common sites for oral melanoma. Oral melanoma can 
present as an unevenly shaped macule, plaque or mass, 
well circumscribed or diffused.
A review of literature revealed fewer than 50 reported 
cases of primary malignant melanoma of the lip. Litera-
ture review till 1997 showed 30 reported cases of mucosal 
melanoma of the lip [4]. The scattered data on mucosal 
melanoma of lip after 1997 shows less than 20 cases of 
mucosal melanoma of lip. A paucity of data elucidating 
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the predictive factors as well as the unpredictable and 
aggressive biologic behavior of mucosal melanoma com-
pounds the vexing clinical scenario (Table 1).
This case presents the aggressive nature of malignant 
mucosal melanoma in 32  years old male and highlights 
the need of careful scrutinization of any pigmented 
lesions in oral cavity and necessity of biopsying lesions 
with potential growth to rule out malignancy.
Case presentation
A 32 years old male of Han ethic group from northeast 
china, driver by occupation, presented to Department of 
Oral and Maxillofacial Surgery, Norman Bethune Hospi-
tal of Stomatology, ChangChun, China with pigmented 
lesions on the upper left lip vermilion during month of 
June 2011. The lesion was noticed for the first time 4 years 
before as a macule of approximately 1 cm × 0.5 cm which 
gradually increased in size without any accompanying 
symptoms and discomfort. He also noticed a change in 
the color of skin of lip above left vermilion after about 
3 years of the changes in the mucosa of the lip.
There is no significant past medical and family history. 
The patient’s family history of any other tumor was also 
inquired but nothing significant was reported. He has 
neither the history of smoking nor drinking.
On extra oral examination, pigmented papules of vari-
ous sizes were seen in the vermilion of upper left lip 
associated with brownish discoloration of the skin above 
vermilion. The skin discoloration was approximately 
0.5 ×  1  cm extending from 0.5  cm medial to left angle 
of mouth to the left philtral ridge (Fig.  1). The lip was 
slightly swollen. On intra-oral examination, the mucosal 
lesion was about 1.5  cm above the vestibule extending 
from labial frenum to 0.5  cm medial to angle of mouth 
on the left side. It was neither indurated nor tender on 
palpation. There were some areas of ulcerations in the 
mucosa.
There was no apparent neck swelling and cervical 
lymph nodes were non palpable (not enlarged). There 
were no similar skin pathology in other parts of body 
except lip.
A complete blood count, biochemical profile and urine 
analysis were done without significant findings. No 
abnormality was detected in the chest X-ray. Computed 
tomography (CT) scan was done to find out the extent 
of the lesion and to rule out local and regional lymphatic 
involvement.
On presentation, presumptive clinical diagnosis of 
mucosal melanoma (MM) was made. A punch biopsy was 
done and the tissue was sent for histopathological analy-
sis. The histologic features were consistent with clinical 
diagnosis of oral mucosal malignant melanoma.
Medical information was provided to the patient and 
his family regarding the diagnosis, staging, therapeutic 
options and prognosis. Excisional biopsy was performed 
with safety margin of 5  mm and frozen section biopsy 
was found to be free of malignant cells. Left nasolabial 
flap was used for reconstruction of the lip and mucosal 
portion of lip was covered with biological membrane and 
bolster dressing was given.
On Jan 2015, after three and half years of first opera-
tion, he presented with similar lesion on the lip. On 
examination, a nodular bulge of 3  ×  2  cm was seen. 
Following the recurrence, the patient presented with 
mucosal macules of 4 × 2 mm and 3 × 2 mm on the ver-
milion of the upper left lip without involvement of the 
skin above vermilion, in contrast to the first presentation 
as papules.
The lesion was more than 2  mm in thickness which 
can be correlated with stage III of Breslow’s classifica-
tion although this classification has not been validated 
as prognostic predictors in oral melanoma due to archi-
tectural differences between oral mucosa and skin. The 
swelling was indurated and non-tender. There was a small 
area of ulceration on mucosa. The pathological report 
showed <1 mitoses per square millimeter. The cervical 
lymph nodes were not palpable. On biopsy, recurrence of 
the oral mucosal melanoma was confirmed. Excision of 
the melanoma was performed with safety margin of 2 cm 
in contrast to 5 mm safety margin during the first opera-
tion. Frozen section confirmed the margins to be free of 
malignant cells. The lip was reconstructed with Abbe-
Estlander flap as well as utilizing tissue from the right 
nasolabial fold as shown in the Fig. 2. The patient denied 
of undergoing radiotherapy treatment after excision. The 
patient is under regular follow up and strictly advised to 
maintain regular follow up every 3 monthly.
Discussion
Primary mucosal melanoma is very rare. The common 
sites for intraoral melanoma are the palate and maxil-
lary gingiva accounting for 80–90 % of the cases, but any 
mucosal site may be involved. The other reported sites are 
labial and buccal mucosa, tongue and floor of the mouth. 
Chaudhary et al. [5], in their study of 105 cases found that 
80 % (93 pts) cases of oral melanoma originated in max-
illa, 51 % (38 pts) limited to hard palate, 26 % (20 pts) to 
alveolar ridge, 8 % (5 pts) to soft palate and 15 % (12 pts) 
of them belonged to more than one locations. Lourenco 
Martin Sangueza et al. recently reported 35 oral mucosal 
melanoma cases, within the Latin American population. 
Most cases (71.42 %) were found in hard palate and upper 
alveolar ridge [6]. Secondary or metastatic lesion may be 
located on the tongue, parotid, and tonsils [7]. In contrast 
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to the above reported literatures, our patient presented 
with the melanoma on the left side of upper lip.
Most studies on melanoma reveal a higher incidence in 
older males showing 2:1 M:F ratio; however, Pour et  al. 
reported a greater prevalence of oral melanoma among 
women [8]. The mean ages of occurrence are between the 
fifth and seventh decades. It is frequently found in people 
over 40 and seldom found in those under 20. The aver-
age age is between 51–60 years in males and 61–70 years 
in females [9]. Oral melanomas arise more frequently 
in Caucasians and Asians, with highest incidence in the 
Japanese [10]. Non-caucasian patients are less likely to 
present with cutaneous melanoma (for example Afri-
cans, due to greater level of melanin than Caucasians) 
but may present with acral lentiginous melanoma or 
mucosal melanoma. Mucosal melanomas account for 
1.3 % of melanomas in whites and 11.8 % of all melano-
mas in blacks [11]. The age of occurrence in our case was 
32 which is not consistent with the other reported cases 
nevertheless the age was above 20 as malignant mela-
noma is not common in patients below 20 years.
Ultra violet (UV) radiation plays a vital role in the 
physiopathology of cutaneous melanomas; oral mucosal 
melanomas usually appear in areas protected from UV 
radiation. Risk factors relative to the development of 
mucosal melanomas are unknown. Apparently there is no 
correlation to chemical, thermal, or physical events, and 
according to a study performed at the Dr. Manuel Gea 
Gonzalez Hospital (by Aguilar et al.) no relationship was 
found between mucosal melanoma and human papilloma 
virus (HPV) infections [9]. The absence of any risk fac-
tors linking to the etiology of mucosal melanoma in our 
patient was consistent with current belief that most oral 
melanomas emerge de novo.
Oral mucosal melanomas (OMM) are indolent and 
asymptomatic until the condition worsens. Most people 
do not inspect their oral mucosa properly until swelling, 
dental mobility, or bleeding occurs. Early lesions appear 
as a variable size pigmented macules whereas long lasting 
lesions can be nodular or pedunculated, pigments vary 
from dark brown to blue, gray purple or black. Neverthe-
less, it is common to find white or red macules, especially 
in swollen lesions.
However, lighter and near normal tissue color 
(amelanotic) can occur and up to one-third of oral 
mucosal melanomas may be amelanotic [7, 12]. For the 
first time, our patient presented with black papules of 
various sizes on the left vermilion along with brownish 
discoloration of skin above vermilion. The patient was 
aware of the changes in his lip since 4 years but reported 
so late. The progression of the lesion is very slow; it’s a 
very late presentation when the tumor has been allowed 
to grow slowly and locally for a long time. Had the 
patient presented earlier, such aggressive excision would 
not have been necessary. This shows that how the patient 
behavior has helped in the progression of the melanoma. 
The patient was cautioned against the chances of local 
recurrence and advised to maintain regular follow-up. 
The patient ignored the follow-up because of its asymp-
tomatic behavior. The patient presented with pigmented 
macules and fibrotic mass on the upper lip during the 
time of recurrence.
Since the clinical manifestation of oral melanoma 
varies as an unevenly shaped macule, plaque or mass, 
well circumscribed or diffused and there is no distinct 
appearance to oral melanoma, the differential diagnosis 
is extensive. It can include Addison disease, blue nevus, 
lentigines, Kaposi sarcoma, oral nevus, amalgam tattoos, 
mucosal melanotic macule, Peutz–Jeghers syndrome, 
Fig. 1 Mucosal melanoma of lip showing pigmented papules involv-
ing adjacent skin. Nasolabial flap design for reconstruction
Fig. 2 Recurrence of mucosal melanoma showing pigmented mac-
ules and a bulge on upper lip. Flap design for reconstruction
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smoker’s melanosis and physiological pigmentation [9]. 
Oral amelanotic melanomas are rare and the prognosis 
is poorer than that of pigmented melanomas because of 
delay in establishing the correct diagnosis and the initia-
tion of treatment. The differential diagnosis of amelanotic 
melanoma includes poorly differentiated carcinoma and 
lymphoma [13].
Initially, oral melanomas are typically asymptomatic; 
however, they can become painful with growth and 
expansion. Ulceration, bleeding, paresthesia, and ill-fit-
ting prostheses are common complaints of patients pre-
senting with late stage disease [7, 14, 15].
The definite diagnosis must be performed through his-
topathological study. The most important histopatho-
logic finding is an epithelioid or fusiform (sarcomatose) 
or neural, melanocytic proliferation in asymmetric shape 
nest arrays. In the dermal epidermis junction, there is 
a predominance of individual cells with an abundant 
eosinophilic, clear cytoplasm, and melanin granules. 
They can have a large nucleolus, with prominent eosino-
philic nucleoli and nuclear pseudo inclusions are found 
due to nuclear membrane irregularities. Necrosis and 
ulcerations are not unusual. Our patient had epithelioid 
melanoma cells invasion into lamina propria. Epithelioid 
melanocytes were arranged in sheets forming islands 
containing large prominent nucleoli and melanin (Fig. 3). 
The histological examination following recurrence 
showed intraepithelial hyperkeratosis, invasion of lamina 
propria by epithelioid melanocytes which were forming 
nests or clumps (Fig.  4). The histopathological differen-
tial diagnosis is extensive; therefore, in some occasions, 
immune-staining is required. Cells are positive for S-100, 
HMB-45, Melan-A, tyrosinase and microphthalmic-
associated transcription factor (MITF) [9]. Amelanotic 
growths do not have melanin-pigmented tumor cells that 
vividly display Hematoxylin and Eosin staining, in which 
cases Immunohistochemistry is fundamental in estab-
lishing the final diagnosis [2].
Greene et  al. [2] proposed three useful criteria in the 
diagnosis of primary oral melanoma. It includes:
1. The presence of clinical and microscopic tumor in 
oral mucosa.
2. The presence of junctional activity.
3. Inability to demonstrate any other primary site.
This patient fulfilled above three criteria for the diag-
nosis of primary oral melanoma and ruled out the possi-
bility of metastasis from another primary melanoma.
Given the propensity for mucosal melanoma to dis-
seminate and to exclude metastatic melanoma from a 
cutaneous primary, a basic metastatic workup should be 
considered. This workup includes serum lactate dehydro-
genase, chest radiograph, and combined positron emis-
sion tomography/computed tomography scanning of the 
chest, abdomen, and pelvis [16]. Considering the fact, 
Chest X-ray and CT of chest, abdomen and pelvis were 
done in our patient to determine the extent of the dis-
order, local or regional involvement of lymphatic nodes 
and to rule out metastatic melanoma from a cutaneous 
primary.
Sentinel-node biopsy beneficial in cutaneous mela-
noma staging is less valuable in staging or treating oral 
melanoma, given they do not predict the tumor’s lym-
phatic drainage due to the existing anatomical ambiguity 
and as a result the erratic drainage does not allow for a 
consistent evaluation of how this method is used. There 
are not many studies regarding the role of sentinel lymph 
Fig. 3 Epithelioid melanoma cells invasion into lamina propria, 
which are arranged in sheets and islands, containing large prominent 
nucleoli and melanin (×4)
Fig. 4 Intraepithelial hyperkeratosis, invasion of lamina propria by 
epithelioid melanocytes, which are forming nests and clumps (×10)
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node biopsy in head and neck mucosal melanoma. In one 
study by Sta’rek et al. in 2006, they found that presence of 
microscopic metastatic focus in the sentinel lymph node 
was associated with an early hematogenous dissemina-
tion. Therefore, sentinel lymph node biopsy, which repre-
sents a potentially efficient staging tool, warrants further 
investigation [17].
The American Joint Committee on Cancer (AJCC), 
Cancer Staging Manual 7th edition (2010) includes a 
newly developed staging system for mucosal melanoma 
of head and neck [18]. The new staging criteria reflect the 
aggressive nature of head neck mucosal melanoma. The 
AJCC staging system for MM begins with stage T3 as the 
most limited form of disease. According to this system, 
our patient is Stage IVA. Mucosal melanoma tumor stag-
ing with negative lymph nodes were proposed by Prasad 
et al. [19] and Patel et al. [20]. Stage I is melanoma in situ 
(non-invasive), Stage II is the one invading the lamina 
propria and Stage III is the one invading deeper tissues. 
According to this staging system, our case falls in Stage II 
as it has invaded lamina propria. Survival average drops 
as stages progresses.
The Clark and Breslow classifications have not been val-
idated as prognostic predictors in oral melanoma due to 
architectural differences between oral mucosa and skin. 
The oral mucosa is thinner than skin and lacks histologi-
cal points of reference similar to the papillary and reticu-
lar dermis, nevertheless, some studies have compared 
oral melanomas with the acral lentiginous melanoma and 
with the cutaneous nodular melanoma [2]. Most authors 
use the classification of the Western Society of Teachers 
of Oral Pathology (WESTOP), which divides them into a 
relatively simple system according to its histopathological 
pattern as: (a) melanoma in situ, delimited to the epider-
mis and its junction with the connective tissue; (b) inva-
sive melanomas, in which the neoplasia extends into the 
connective tissue and (c) melanomas with a combined 
pattern between invasive and in situ [21]. So far our case 
is concerned, the neoplastic cells extended into the con-
nective tissues.
C-KIT is a key regulator of growth, differentiation, 
migration, and proliferation of melanocytes [22]. It has 
been shown to recruit and activate a number of intracel-
lular signaling pathways implicated in tumor progres-
sion, such as the phosphoinositide 3-kinase/AKT, Src, 
mitogen-activated protein kinase, Janus kinase, signal 
transducers and activators of transcription, and phos-
pholipase-C-g pathways [23]. Activating mutations in 
the c-KIT gene are detected in a significant number of 
patients with mucosal melanoma. The mitogen-activated 
protein kinase (MAPK) pathway (RAS/MEK/ERK) is a 
critical growth cascade in oral mucosal melanoma and 
it is the most common pathway described in oncogenic 
events during the progression of melanoma [24]. The 
MAPK pathway is downstream of the receptor tyros-
ine kinases, cytokines and G protein-coupled recep-
tors, leading to cell growth, survival and differentiation. 
Molecules that participates in this signal transduction 
pathway are RAF (three isoforms ARAF, BRAF, CRAF) 
and RAS. RAS is encoded by the RAS gene, consisting 
of three isoforms HRAS, KRAS and NRAS. The intense 
RAS protein expression in both the in  situ and invasive 
phases of oral mucosal melanoma (OMM) may suggest 
that RAS overexpression is necessary in OMM progres-
sion. A review of literature reports that 14 % of mucosal 
melanomas harbor activating c-KIT mutations; 5  % 
showed BRAF mutation and 14  % oncogenic mutations 
in NRAS, which is much lower than the reported BRAF 
prevalence (56–59  %) in cutaneous melanoma [25]. In 
addition, the MAPK pathway may be triggered by the 
activation of c-KIT, leading to the induction of signal-
ing proteins, essentially stuck in the ‘on’ position, result-
ing in uncontrolled cell proliferation and survival [22]. 
Mutations in the c-KIT gene, along with overexpression 
of RAS in part, considered to be involved in the mecha-
nism of development and progression of melanoma, have 
been identified in mucosal melanoma, suggesting c-KIT 
and RAS as a promising molecular target. Thus, drug 
therapies have been developed to inhibit these mutations, 
preventing tumor proliferation. The frequency of intense 
NRAS protein expression, BRAF and c-KIT activating 
mutations indicates that overlapping of molecular activi-
ties may occur in OMM progression posing a major con-
cern in OMM therapy [26]. Such complex interactions of 
signal protein at multiple levels and with multiple path-
ways may require combinations of targeted therapies, 
rather than a single agent. Such tests for cKIT and RAS 
mutation as well as advanced targeted therapies are not 
available in our centre.
The best-validated targeted drugs in melanoma are 
the selective BRAF inhibitors vemurafenib (PLX4032, 
Zelboraf™) and dabrafenib (GSK2118436, Tafinlar™) as 
well as the LGX818 (Novartis) compound that appears 
to have the highest affinity for the catalytic domain of 
the kinase. All of them are relatively selective for their 
intended target V600E BRAF, with little cross-reactivity 
for wild-type BRAF and CRAF. These molecules selec-
tively inhibit the growth of cells that harbour a V600 
BRAF mutation. Vemurafenib and dabrafenib have both 
demonstrated impressive clinical efficacy with response 
rates in the region of 50  % in V600 BRAF mutated 
advanced melanoma. In contrast to BRAF mutated mela-
noma, the kinase inhibitor imatinib has proven efficacy 
in patients with advanced melanoma harbouring KIT 
mutations. KIT mutations are found at low frequencies 
(≤10  %) in melanomas arising from mucosal or acral 
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lentiginous surfaces [27]. 50 % of patients who are treated 
with BRAF or MEK inhibitors have disease progression 
within 6–7 months after the initiation of treatment. Sev-
eral mechanisms mediating resistance to BRAF inhibi-
tors through MAPK reactivation have been described, 
including the up-regulation of bypass pathways medi-
ated by cancer Osaka thyroid kinase (COT), development 
of de novo NRAS or MEK mutations, and dimerization 
or variant splicing of mutant BRAF V600. A study con-
ducted by Keith T. Flaherty et al. in 2012 concluded that 
the combination of the BRAF inhibitor dabrafenib and 
the MEK inhibitor trametinib in patients with metastatic 
BRAF V600 melanoma, represents one strategy for delay-
ing the emergence of this resistance mechanism (median 
duration of response for combination therapy 10.5 vs 
5.6 months for dabrafenib monotherapy) [28].
Surgical resection when feasible remains the treat-
ment of choice for oral melanomas. Adjunctive therapy 
(immuno/chemo/radio) is also often advocated. How-
ever, the literature reports no improvement with adjunc-
tive therapies as it pertains to the overall survival rate 
[29, 30]. Recent reports supporting the use of biochemo-
therapy (combination of chemotherapy +  interleukin 2/
interferon) have been encouraging. Sun et al. found a sig-
nificantly higher 5  year survival rate in patients treated 
with surgery and biochemotherapy when compared to 
those treated with surgery, chemotherapy, surgery and 
chemotherapy, or surgery and radiotherapy (58.4 vs 
20.7 %). Our patient did not wish to undergo radiother-
apy due to non-involvement of cervical lymph nodes.
Elective neck dissection was not performed in our 
patient as cervical lymphadenopathy was absent and also 
considering the fact that prophylactic lymph node dis-
section does not impact outcomes and is reserved for 
patients with clinically evident nodal involvement [16]. 
The enbloc resection decreases the chances the local 
recurrence rate, with little effect on metastasis and sur-
vival. Therapeutic neck dissection is to be done in cases 
of palpable lymph nodes but there is disagreement over 
neck dissection be done in absence of clinically palpable 
nodes [1].
Immunotherapy is useful in the treatment of mela-
noma at high risk for recurrence and for metastatic mela-
noma. Interleukin-2 (IL-2) was the first immunotherapy 
to be approved for metastatic melanoma (1998) and was 
approved on the basis of long-lasting complete response. 
Immunotherapy with BCG (Bacilli Calmette Guerin) 
which sometimes is used in patient with the intent of 
activating the host immune response has also been used 
but with little success. Other immunotherapeutic drug 
includes interferon and cimetidine, which when used 
together is believed to attack killer T cell and inhibit 
suppressor T cells which result in reduction of tumor 
size. Interferon injections have been of some benefits in 
patient with cutaneous and some metastatic melanoma, 
but the response to oral melanoma remains uncertain. 
Ipilimumab, an antibody that blocks the cytotoxic T-lym-
phocyte antigen-4 (CTLA-4) immune checkpoint, is 
approved by the United States Food and Drug Adminis-
tration (FDA) in 2011 based on an overall survival (OS) 
advantage in patients with metastatic melanoma, how-
ever its efficacy in mucosal melanoma is not clear yet 
[31]. Programmed cell death-1 (PD-1), an immunoin-
hibitory receptor of the CD28 family, plays a major role 
in tumor immune escape. The interaction of PD-1 with 
its two ligands, B7-H1 and B7-DC (PD-L1 and PD-L2), 
occurs predominantly in peripheral tissues including 
the tumor microenvironment and leads to apoptosis and 
downregulation of T-cell effector function [32]. Mono-
clonal antibodies against PD1 and its ligand (PD-L1), the 
second generation immunomodulatory antibodies, dis-
played significant durable benefits in patients with MM 
[33]. Pembrolizumab and Nivolumab are the first and the 
second anti-PD-1 drug to receive accelerated approval 
in 2014 for demonstrating durable responses in patients 
whose disease has progressed following ipilimumab and, 
if BRAF V600 mutation positive, also a BRAF inhibitor.
Although previously melanoma was considered to 
be radioresistant, radiotherapy is now considered to be 
important adjuvant in achieving local control and may 
even has merit as primary therapeutic modality [34]. 
Furthermore, primary irradiation is considered as viable 
alternative to surgery for inoperable cases. It has also 
been used as an adjuvant treatment for recurrences, pal-
liative treatment or postsurgical when the margins are 
doubtful.
While the recommended treatment is ablative surgery 
with tumor free margins and to a lesser extent, immu-
notherapy or radiotherapy, there is a recognized need 
for evidence based treatment protocol. Multimodality 
treatment may be more beneficial in the treatment of 
mucosal melanoma. It is apparent, however, that oral 
melanomas are much more aggressive than their cutane-
ous counterpart. The more aggressive behavior has been 
attributed to angioinvasion, anatomic relation that pre-
cludes adequate surgical removal, and delay in diagnosis, 
tendency to early ulceration owing to repeated trauma, 
which in turn may establish avenues for metastasis and 
higher rate of regional and systemic spread. Our case 
can be considered to be aggressive as there was recur-
rence following 3 and half years despite of tumor free 
margins, anatomical constraints due to esthetics and 
tendency to ulceration due to chances of trauma to lips. 
Literature also claims that patients with lesions under 
2 mm in thickness have an important survival rate over 
those with lesions greater than 2 mm. Our patient having 
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a lesion of over 2  mm thickness has a recurrence after 
3 and half years with no distant metastasis. If lymphatic 
glands are affected prognosis drops down. Prognosis 
improves with early detection and total removal of lesion 
before it spreads. Eighty percent (80 %) of patients with 
oral mucosal melanoma have a local disease, 5–10  % 
of cases have neck and/or subclavian lymphatic node 
involvement. After complete removal, 10–20 % regional 
relapses have been reported with a 10–25 % 5 years sur-
vival rate [9].
Conclusion
Oral melanoma is a rarer lesion which basically origi-
nates from the malignant transformation of melanocytes. 
There are no specific etiological factors identified for oral 
melanomas. So, clinician’s must be always vigilant to find 
these rare lesions, and pigmented lesions with growth 
potential should be submitted to biopsy to rule out 
malignancy. The patient should also be conscious enough 
to report pigmented lesions as soon as he/she is aware of 
it despite of it being asymptomatic so as to avoid aggres-
sive treatment. Vigilant comprehensive analysis of pub-
lished cases and recognition of new ones may be helpful 
in establishing definite classification and proposing clini-
cal features that would facilitate its early diagnosis, as a 
prerequisite for timely treatment and better prognosis of 
this rare pathology.
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